Wungki Park, Gastrointestinal Oncologist at the Memorial Sloan Kettering Cancer Center, shared on X:
”POLAR maintenance: Cohort A HRD by BRCA2, PALB2, BRCA1 pembro + olaparib (no chemo) ORR 35%, 6M PFS rate 62% [47-82] maturing 3YOS rate 58% and rare outlier patients in Cohorts B and C. Ongoing deep science.”
Source: Wungki Park/X
